Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2017

Primary Completion Date

August 17, 2017

Study Completion Date

June 30, 2022

Conditions
Soft Tissue Sarcomas
Interventions
BIOLOGICAL

Nivolumab

Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.

DRUG

Pazopanib

Pazopanib given at a dose of 800 mg by mouth daily.

Trial Locations (1)

10016

New York University School of Medicine, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

NYU Langone Health

OTHER